Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

The convergence of maturing technology, growing industry demand for combination therapy, and regulatory innovation have given rise to Blueprint Medicines, a pure-play kinase specialist that aspires to become a US-focused cancer company.

U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.